Флудеоксиглюкоза (18f) Ge Healthcare

Fludeoxyglucose (18F) is a radiopharmaceutical used in PET imaging for metabolic activity assessment. This sterile, injectable solution helps visualize glucose metabolism in tissues. Short half-life requires prompt use after preparation. Suitable for oncology, neurology and cardiology scans.

Fludeoxyglucose (18F) is used in positron emission tomography (PET) imaging to evaluate metabolic activity within the body. It helps identify areas of abnormal glucose metabolism often associated with cancer, neurological disorders or cardiac conditions. The radiotracer accumulates in tissues with high metabolic rates, aiding in diagnosis and treatment planning.

After intravenous injection, Fludeoxyglucose (18F) distributes throughout the body and accumulates in tissues with high glucose uptake. The radioactive signal is detected by PET scanners to create detailed images of metabolic activity. Patients typically experience no immediate physiological effects from the radiotracer itself.

Fludeoxyglucose (18F) should be handled by trained medical professionals in controlled clinical settings. Pregnant or breastfeeding individuals should avoid exposure due to radiation risks. Patients are advised to minimize close contact with others for several hours post-injection to reduce radiation exposure to others.

No known drug interactions exist with Fludeoxyglucose (18F) as it is a radiopharmaceutical rather than a conventional medication. However, recent chemotherapy, radiation therapy or other diagnostic procedures may affect imaging results. Patients should disclose all medications and recent medical procedures to their healthcare provider.